Ingo Lindner

Title: Ingo Lindner: Innovator in Cancer Assessment

Introduction

Ingo Lindner is a notable inventor based in Penzberg, Germany. He has made significant contributions to the field of cancer assessment through his innovative research and development. His work focuses on the use of specific proteins as markers for various types of cancer, which can aid in early detection and patient surveillance.

Latest Patents

Ingo Lindner holds a patent for a method that utilizes the arginine-rich metastasized in early tumors protein, known as ARMET, as a universal marker for different cancer types. This patent outlines a method for assessing cancer, particularly pulmonary or lung cancer and colon cancer. The use of ARMET can potentially assist in the early detection of various cancers, including breast, ovarian, cervical, and melanoma, among others. The method involves measuring ARMET in a liquid sample derived from an individual, which can be crucial for monitoring patients who have undergone surgery.

Career Highlights

Ingo Lindner is currently employed at Roche Diagnostics Operations, Inc., where he continues to advance his research in cancer diagnostics. His work has garnered attention for its potential to improve cancer assessment methods and enhance patient outcomes.

Collaborations

Ingo collaborates with talented colleagues such as Markus Roessler and Julia Riedlinger, contributing to a dynamic research environment focused on innovative solutions in healthcare.

Conclusion

Ingo Lindner's contributions to cancer assessment through his patent on ARMET highlight the importance of innovation in medical research. His work exemplifies the potential for scientific advancements to improve early detection and treatment of cancer, ultimately benefiting patients worldwide.